The advent of mRNA vaccines against SARS-CoV-2 in 2020 changed the course of the COVID-19 pandemic. Now, the Nobel ...
The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of ...
A graphic of a purple and magenta Cas9 protein, which is a somewhat round, but uneven, ball, bound to a yellow and orange ...
Mayo Clinic scientists are exploring an unusual but promising strategy to treat one of the deadliest bile duct cancers by turning milk into a microscopic delivery system for gene therapy. Their work ...
Researchers have found a way to make cancer-killing immune cells more powerful and precise. By adding specific signaling components, they boosted the cells’ readiness to attack tumors. Surprisingly, ...
Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR.
Verrica Pharmaceuticals Inc. ("Verrica") (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological ...
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications ...
Location: (Salons B,C,D - Lower Level, Hilton Chicago) ...
Zacks Small Cap Research on MSN
HURA: 2025 financial results
By John Vandermosten, CFA NASDAQ: HURA READ THE FULL HURA RESEARCH REPORT Operational and Financial Results On April 1st, ...
A technique that transforms immune cells into cancer-seeking bloodhounds may overcome a roadblock that has hampered immunotherapy for solid tumors, according to a new study by Stanford Medicine ...
A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a “masked T-cell engager”. This type of immunotherapy ignites our own ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results